Feasibility & Site Selection

Conducting Accurate and Effective Feasibilities in Clinical Trials is
An Investment to Ensure a Successful Study

Feasiblity & Site Selection

Conducting Accurate and Effective Feasibilities in Clinical Trials is
An Investment to Ensure a Successful Study

About 35% of delays in studies are due to patient recruitment, nearly one-fifth of the participating investigators do not enroll any patients and about one-third only enroll 5% of potential patients. Therefore, conducting accurate and effective feasibilities in clinical trials is crucial for a successful study.

This process not only includes the verification of the study design by experts reviewing the clinical trial protocol. Finding the right sites and countries for your study is of utmost importance.

Exom has established a streamlined eFeasibility process, utilizing the power of Exom’s Genius SUITE, supporting you from initial site contact to collection of essential documents for submission to EC/IRB and competent authorities.

Using our Genius “eStudy Feasibility & Accelerator Suite” we are able to conduct the entire feasibility process in an average of 38 days, from the preparation of an adequate feasibility questionnaire to first regulatory submission.

Median return time of signed CDA

Median return time of filled questionnaires

Median collection time of essential documents

Time to first regulatory submission from eFeasibility start

We help you as a study sponsor to identify solutions to mitigate the costs and risks associated with a particular trial. In a true sense, an accurate and effective feasibility is an investment to ensure a successful study.


Program Level
They are mainly aimed towards finding prevalence of particular diseases or conditions in a particular region and hence include clinical and epidemiological information.

  • Ethical and Regulatory: Program feasibilities aim towards finding overall time for clinical trial approval, particular regulatory requirements which can affect decision related to placing of the study etc
  • Medical: Disease frequency, prevalence of program-specific patient population, nature of existing treatment patterns or guidelines, presence of alternative drugs and treatments.
Study Level

Study level feasibilities are more customized towards assessing whether a particular clinical study can be conducted in a country or region.
Clinical aspects
This relates to the epidemiological data on the study specific population in terms of stage of disease, availability of standard care (in terms of background therapy and comparators), specific agreement with inclusion and exclusion criteria and acceptance of study specific procedures in line with existing medical practices.
This would include the assessment specific regulatory requirements and of the overall approval timelines to get the study ongoing.

Site or Investigator Level
This is actually the micro- feasibility of paramount importance – deciding whether to work with an investigator or not and identifying challenges and probable solutions. It consists of the following.

  • Clinical aspects: Assessing the investigator’s readiness in terms of standard care (e.g., type of drugs, dosage), actual study population vs. the patient population treated or seen by the potential investigator, readiness and acceptance of background and comparative therapy and familiarity with use of tools and technology is done in investigator level feasibility.
  • Site demographics: Site demographics help us in assessing the type of clinical practice (hospital vs. out-patient), prior experience in clinical trials, and availability of study coordinators, pharmacists and nurses. This helps in assessing the ‘competency’ of the investigator/ site to conduct the clinical trial, not necessarily in terms of medical knowledge but more in terms of protocol related knowledge, personnel availability etc.
  • Recruitment and retention: This is the most important section of the site feasibility. It helps us in finding the recruitment potential, specifically in anticipated subjects per month and in the entire trial. Other information collated includes ethical considerations, presence of competitive studies, prior experience in conducting similar studies etc.
  • Ethical aspects: This also helps in site start-up and planning. It includes ethics committee requirements, requirements of translations etc and overall process of ethics clearance.
  • Site infrastructure: Most clinical studies have specific requirements related to drug storage, processing of biological samples e.g. refrigerated centrifuge etc. Hence it is important to assess site’s capabilities related to such requirements, whether it is available at the site or needs to be procured, whether there are team members who have the relevant expertise to conduct these activities and use such tools.
  • Quality: One more aspect which also needs to be evaluated is whether sites have undergone sponsor or regulatory agencies independent site audits in the past. This also helps in allocating appropriate resources and providing adequate training in the start up period.
Share This

Exom is now Kapadi


Once three entities – OncoBay Clinical, Clinscience, and Exom Group s.r.l – now we stand as one, bringing forth a symphony of expertise and seamless operations. To celebrate our unity, we re-brand under the banner of Kapadi, and embark on a new chapter of exceptional service in oncology clinical research.

Kapadi is not just a name; it's a testament to our fusion. It signifies the our standing as a global CRO powerhouse committed to accelerating groundbreaking cancer therapies that uplift patients worldwide. From conceptualizing studies, navigating regulations, and analyzing data, we provide a comprehensive array of services designed to empower your oncology clinical trials.

Visit Kapadi.com